Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells

Cell Death Differ. 2020 Aug;27(8):2531-2533. doi: 10.1038/s41418-020-0576-2. Epub 2020 Jun 18.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinogenesis / metabolism
  • Carcinogenesis / pathology*
  • Cell Death / drug effects
  • Kaplan-Meier Estimate
  • Lymphoma / drug therapy*
  • Lymphoma / metabolism
  • Lymphoma / pathology*
  • Mice, Transgenic
  • Proto-Oncogene Proteins c-myc / metabolism*
  • Receptor-Interacting Protein Serine-Threonine Kinases / deficiency*
  • Receptor-Interacting Protein Serine-Threonine Kinases / metabolism

Substances

  • Antineoplastic Agents
  • Proto-Oncogene Proteins c-myc
  • Receptor-Interacting Protein Serine-Threonine Kinases
  • Ripk3 protein, mouse